Carrageenan oligosaccharides and associated carrageenan-degrading bacteria induce intestinal inflammation in germ-free mice
Carrageenans (CGNs) are widely used in foods and pharmaceuticals although their safety remains controversial. To investigate the effects of CGNs and CGN-degrading bacteria in the human colon, we screened for CGN degradation by human fecal microbiota, and for inflammatory response to CGNs and/or CGN-...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Yin, Yeshi [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2021transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
10 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Outcomes and complications of triceps tendon repair following acute rupture in American military personnel - Balazs, George C. ELSEVIER, 2016, JGG, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:48 ; year:2021 ; number:9 ; day:20 ; month:09 ; pages:815-824 ; extent:10 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.jgg.2021.08.001 |
|---|
| Katalog-ID: |
ELV055570380 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV055570380 | ||
| 003 | DE-627 | ||
| 005 | 20230626041840.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220105s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jgg.2021.08.001 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001629.pica |
| 035 | |a (DE-627)ELV055570380 | ||
| 035 | |a (ELSEVIER)S1673-8527(21)00245-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 660 |q VZ |
| 082 | 0 | 4 | |a 660 |q VZ |
| 084 | |a 58.10 |2 bkl | ||
| 100 | 1 | |a Yin, Yeshi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Carrageenan oligosaccharides and associated carrageenan-degrading bacteria induce intestinal inflammation in germ-free mice |
| 264 | 1 | |c 2021transfer abstract | |
| 300 | |a 10 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Carrageenans (CGNs) are widely used in foods and pharmaceuticals although their safety remains controversial. To investigate the effects of CGNs and CGN-degrading bacteria in the human colon, we screened for CGN degradation by human fecal microbiota, and for inflammatory response to CGNs and/or CGN-degrading bacteria in germ free mice. Thin-layer chromatography indicated that high molecular weight (MW) CGNs (≥100 kDa) remained undegraded in the presence of human fecal microbiota, whereas low MW CGNs, i.e., κ-carrageenan oligosaccharides (KCO, ~4.5 kDa) were degraded when exposed to seven of eight human fecal samples, although sulfate groups were not removed during degradation. Bacteroides xylanisolvens and Escherichia coli isolates from fecal samples apparently degraded KCO synergistically, with B. xylanisolvens serving as the primary degrader. Combined treatment of KCO with KCO-degrading bacteria led to greater pro-inflammatory effects in the colon and rectum of germ-free mice than either KCO or bacteria alone. Similarly, p-p38-, CD3-, and CD79a-positive immune cells were more abundant in combined treatment group mice than in either single treatment group. Our study shows that KCO-degrading bacteria and the low MW products of KCO can promote proinflammatory effects in mice, and represent two key markers for evaluating CGN safety in foods or medicines. | ||
| 520 | |a Carrageenans (CGNs) are widely used in foods and pharmaceuticals although their safety remains controversial. To investigate the effects of CGNs and CGN-degrading bacteria in the human colon, we screened for CGN degradation by human fecal microbiota, and for inflammatory response to CGNs and/or CGN-degrading bacteria in germ free mice. Thin-layer chromatography indicated that high molecular weight (MW) CGNs (≥100 kDa) remained undegraded in the presence of human fecal microbiota, whereas low MW CGNs, i.e., κ-carrageenan oligosaccharides (KCO, ~4.5 kDa) were degraded when exposed to seven of eight human fecal samples, although sulfate groups were not removed during degradation. Bacteroides xylanisolvens and Escherichia coli isolates from fecal samples apparently degraded KCO synergistically, with B. xylanisolvens serving as the primary degrader. Combined treatment of KCO with KCO-degrading bacteria led to greater pro-inflammatory effects in the colon and rectum of germ-free mice than either KCO or bacteria alone. Similarly, p-p38-, CD3-, and CD79a-positive immune cells were more abundant in combined treatment group mice than in either single treatment group. Our study shows that KCO-degrading bacteria and the low MW products of KCO can promote proinflammatory effects in mice, and represent two key markers for evaluating CGN safety in foods or medicines. | ||
| 650 | 7 | |a Carrageenan oligosaccharides |2 Elsevier | |
| 650 | 7 | |a Intestinal inflammatory |2 Elsevier | |
| 650 | 7 | |a Germ-free mouse |2 Elsevier | |
| 650 | 7 | |a Oligosaccharide degrading bacteria |2 Elsevier | |
| 650 | 7 | |a Carrageenans |2 Elsevier | |
| 700 | 1 | |a Li, Miaomiao |4 oth | |
| 700 | 1 | |a Gu, Weizhong |4 oth | |
| 700 | 1 | |a Zeng, Benhua |4 oth | |
| 700 | 1 | |a Liu, Wei |4 oth | |
| 700 | 1 | |a Zhu, Liying |4 oth | |
| 700 | 1 | |a Pi, Xionge |4 oth | |
| 700 | 1 | |a Primerano, Donald A. |4 oth | |
| 700 | 1 | |a Yu, Hongwei D. |4 oth | |
| 700 | 1 | |a Wei, Hong |4 oth | |
| 700 | 1 | |a Yu, Guangli |4 oth | |
| 700 | 1 | |a Wang, Xin |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a Balazs, George C. ELSEVIER |t Outcomes and complications of triceps tendon repair following acute rupture in American military personnel |d 2016 |d JGG |g Amsterdam [u.a.] |w (DE-627)ELV024886548 |
| 773 | 1 | 8 | |g volume:48 |g year:2021 |g number:9 |g day:20 |g month:09 |g pages:815-824 |g extent:10 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jgg.2021.08.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_121 | ||
| 912 | |a GBV_ILN_130 | ||
| 912 | |a GBV_ILN_370 | ||
| 912 | |a GBV_ILN_2011 | ||
| 912 | |a GBV_ILN_2031 | ||
| 912 | |a GBV_ILN_2046 | ||
| 936 | b | k | |a 58.10 |j Verfahrenstechnik: Allgemeines |q VZ |
| 951 | |a AR | ||
| 952 | |d 48 |j 2021 |e 9 |b 20 |c 0920 |h 815-824 |g 10 | ||
| author_variant |
y y yy |
|---|---|
| matchkey_str |
yinyeshilimiaomiaoguweizhongzengbenhuali:2021----:argeaoioacaieadsoitdargeadgaigatranuenet |
| hierarchy_sort_str |
2021transfer abstract |
| bklnumber |
58.10 |
| publishDate |
2021 |
| allfields |
10.1016/j.jgg.2021.08.001 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001629.pica (DE-627)ELV055570380 (ELSEVIER)S1673-8527(21)00245-9 DE-627 ger DE-627 rakwb eng 610 VZ 660 VZ 660 VZ 58.10 bkl Yin, Yeshi verfasserin aut Carrageenan oligosaccharides and associated carrageenan-degrading bacteria induce intestinal inflammation in germ-free mice 2021transfer abstract 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Carrageenans (CGNs) are widely used in foods and pharmaceuticals although their safety remains controversial. To investigate the effects of CGNs and CGN-degrading bacteria in the human colon, we screened for CGN degradation by human fecal microbiota, and for inflammatory response to CGNs and/or CGN-degrading bacteria in germ free mice. Thin-layer chromatography indicated that high molecular weight (MW) CGNs (≥100 kDa) remained undegraded in the presence of human fecal microbiota, whereas low MW CGNs, i.e., κ-carrageenan oligosaccharides (KCO, ~4.5 kDa) were degraded when exposed to seven of eight human fecal samples, although sulfate groups were not removed during degradation. Bacteroides xylanisolvens and Escherichia coli isolates from fecal samples apparently degraded KCO synergistically, with B. xylanisolvens serving as the primary degrader. Combined treatment of KCO with KCO-degrading bacteria led to greater pro-inflammatory effects in the colon and rectum of germ-free mice than either KCO or bacteria alone. Similarly, p-p38-, CD3-, and CD79a-positive immune cells were more abundant in combined treatment group mice than in either single treatment group. Our study shows that KCO-degrading bacteria and the low MW products of KCO can promote proinflammatory effects in mice, and represent two key markers for evaluating CGN safety in foods or medicines. Carrageenans (CGNs) are widely used in foods and pharmaceuticals although their safety remains controversial. To investigate the effects of CGNs and CGN-degrading bacteria in the human colon, we screened for CGN degradation by human fecal microbiota, and for inflammatory response to CGNs and/or CGN-degrading bacteria in germ free mice. Thin-layer chromatography indicated that high molecular weight (MW) CGNs (≥100 kDa) remained undegraded in the presence of human fecal microbiota, whereas low MW CGNs, i.e., κ-carrageenan oligosaccharides (KCO, ~4.5 kDa) were degraded when exposed to seven of eight human fecal samples, although sulfate groups were not removed during degradation. Bacteroides xylanisolvens and Escherichia coli isolates from fecal samples apparently degraded KCO synergistically, with B. xylanisolvens serving as the primary degrader. Combined treatment of KCO with KCO-degrading bacteria led to greater pro-inflammatory effects in the colon and rectum of germ-free mice than either KCO or bacteria alone. Similarly, p-p38-, CD3-, and CD79a-positive immune cells were more abundant in combined treatment group mice than in either single treatment group. Our study shows that KCO-degrading bacteria and the low MW products of KCO can promote proinflammatory effects in mice, and represent two key markers for evaluating CGN safety in foods or medicines. Carrageenan oligosaccharides Elsevier Intestinal inflammatory Elsevier Germ-free mouse Elsevier Oligosaccharide degrading bacteria Elsevier Carrageenans Elsevier Li, Miaomiao oth Gu, Weizhong oth Zeng, Benhua oth Liu, Wei oth Zhu, Liying oth Pi, Xionge oth Primerano, Donald A. oth Yu, Hongwei D. oth Wei, Hong oth Yu, Guangli oth Wang, Xin oth Enthalten in Elsevier Balazs, George C. ELSEVIER Outcomes and complications of triceps tendon repair following acute rupture in American military personnel 2016 JGG Amsterdam [u.a.] (DE-627)ELV024886548 volume:48 year:2021 number:9 day:20 month:09 pages:815-824 extent:10 https://doi.org/10.1016/j.jgg.2021.08.001 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_20 GBV_ILN_110 GBV_ILN_121 GBV_ILN_130 GBV_ILN_370 GBV_ILN_2011 GBV_ILN_2031 GBV_ILN_2046 58.10 Verfahrenstechnik: Allgemeines VZ AR 48 2021 9 20 0920 815-824 10 |
| spelling |
10.1016/j.jgg.2021.08.001 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001629.pica (DE-627)ELV055570380 (ELSEVIER)S1673-8527(21)00245-9 DE-627 ger DE-627 rakwb eng 610 VZ 660 VZ 660 VZ 58.10 bkl Yin, Yeshi verfasserin aut Carrageenan oligosaccharides and associated carrageenan-degrading bacteria induce intestinal inflammation in germ-free mice 2021transfer abstract 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Carrageenans (CGNs) are widely used in foods and pharmaceuticals although their safety remains controversial. To investigate the effects of CGNs and CGN-degrading bacteria in the human colon, we screened for CGN degradation by human fecal microbiota, and for inflammatory response to CGNs and/or CGN-degrading bacteria in germ free mice. Thin-layer chromatography indicated that high molecular weight (MW) CGNs (≥100 kDa) remained undegraded in the presence of human fecal microbiota, whereas low MW CGNs, i.e., κ-carrageenan oligosaccharides (KCO, ~4.5 kDa) were degraded when exposed to seven of eight human fecal samples, although sulfate groups were not removed during degradation. Bacteroides xylanisolvens and Escherichia coli isolates from fecal samples apparently degraded KCO synergistically, with B. xylanisolvens serving as the primary degrader. Combined treatment of KCO with KCO-degrading bacteria led to greater pro-inflammatory effects in the colon and rectum of germ-free mice than either KCO or bacteria alone. Similarly, p-p38-, CD3-, and CD79a-positive immune cells were more abundant in combined treatment group mice than in either single treatment group. Our study shows that KCO-degrading bacteria and the low MW products of KCO can promote proinflammatory effects in mice, and represent two key markers for evaluating CGN safety in foods or medicines. Carrageenans (CGNs) are widely used in foods and pharmaceuticals although their safety remains controversial. To investigate the effects of CGNs and CGN-degrading bacteria in the human colon, we screened for CGN degradation by human fecal microbiota, and for inflammatory response to CGNs and/or CGN-degrading bacteria in germ free mice. Thin-layer chromatography indicated that high molecular weight (MW) CGNs (≥100 kDa) remained undegraded in the presence of human fecal microbiota, whereas low MW CGNs, i.e., κ-carrageenan oligosaccharides (KCO, ~4.5 kDa) were degraded when exposed to seven of eight human fecal samples, although sulfate groups were not removed during degradation. Bacteroides xylanisolvens and Escherichia coli isolates from fecal samples apparently degraded KCO synergistically, with B. xylanisolvens serving as the primary degrader. Combined treatment of KCO with KCO-degrading bacteria led to greater pro-inflammatory effects in the colon and rectum of germ-free mice than either KCO or bacteria alone. Similarly, p-p38-, CD3-, and CD79a-positive immune cells were more abundant in combined treatment group mice than in either single treatment group. Our study shows that KCO-degrading bacteria and the low MW products of KCO can promote proinflammatory effects in mice, and represent two key markers for evaluating CGN safety in foods or medicines. Carrageenan oligosaccharides Elsevier Intestinal inflammatory Elsevier Germ-free mouse Elsevier Oligosaccharide degrading bacteria Elsevier Carrageenans Elsevier Li, Miaomiao oth Gu, Weizhong oth Zeng, Benhua oth Liu, Wei oth Zhu, Liying oth Pi, Xionge oth Primerano, Donald A. oth Yu, Hongwei D. oth Wei, Hong oth Yu, Guangli oth Wang, Xin oth Enthalten in Elsevier Balazs, George C. ELSEVIER Outcomes and complications of triceps tendon repair following acute rupture in American military personnel 2016 JGG Amsterdam [u.a.] (DE-627)ELV024886548 volume:48 year:2021 number:9 day:20 month:09 pages:815-824 extent:10 https://doi.org/10.1016/j.jgg.2021.08.001 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_20 GBV_ILN_110 GBV_ILN_121 GBV_ILN_130 GBV_ILN_370 GBV_ILN_2011 GBV_ILN_2031 GBV_ILN_2046 58.10 Verfahrenstechnik: Allgemeines VZ AR 48 2021 9 20 0920 815-824 10 |
| allfields_unstemmed |
10.1016/j.jgg.2021.08.001 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001629.pica (DE-627)ELV055570380 (ELSEVIER)S1673-8527(21)00245-9 DE-627 ger DE-627 rakwb eng 610 VZ 660 VZ 660 VZ 58.10 bkl Yin, Yeshi verfasserin aut Carrageenan oligosaccharides and associated carrageenan-degrading bacteria induce intestinal inflammation in germ-free mice 2021transfer abstract 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Carrageenans (CGNs) are widely used in foods and pharmaceuticals although their safety remains controversial. To investigate the effects of CGNs and CGN-degrading bacteria in the human colon, we screened for CGN degradation by human fecal microbiota, and for inflammatory response to CGNs and/or CGN-degrading bacteria in germ free mice. Thin-layer chromatography indicated that high molecular weight (MW) CGNs (≥100 kDa) remained undegraded in the presence of human fecal microbiota, whereas low MW CGNs, i.e., κ-carrageenan oligosaccharides (KCO, ~4.5 kDa) were degraded when exposed to seven of eight human fecal samples, although sulfate groups were not removed during degradation. Bacteroides xylanisolvens and Escherichia coli isolates from fecal samples apparently degraded KCO synergistically, with B. xylanisolvens serving as the primary degrader. Combined treatment of KCO with KCO-degrading bacteria led to greater pro-inflammatory effects in the colon and rectum of germ-free mice than either KCO or bacteria alone. Similarly, p-p38-, CD3-, and CD79a-positive immune cells were more abundant in combined treatment group mice than in either single treatment group. Our study shows that KCO-degrading bacteria and the low MW products of KCO can promote proinflammatory effects in mice, and represent two key markers for evaluating CGN safety in foods or medicines. Carrageenans (CGNs) are widely used in foods and pharmaceuticals although their safety remains controversial. To investigate the effects of CGNs and CGN-degrading bacteria in the human colon, we screened for CGN degradation by human fecal microbiota, and for inflammatory response to CGNs and/or CGN-degrading bacteria in germ free mice. Thin-layer chromatography indicated that high molecular weight (MW) CGNs (≥100 kDa) remained undegraded in the presence of human fecal microbiota, whereas low MW CGNs, i.e., κ-carrageenan oligosaccharides (KCO, ~4.5 kDa) were degraded when exposed to seven of eight human fecal samples, although sulfate groups were not removed during degradation. Bacteroides xylanisolvens and Escherichia coli isolates from fecal samples apparently degraded KCO synergistically, with B. xylanisolvens serving as the primary degrader. Combined treatment of KCO with KCO-degrading bacteria led to greater pro-inflammatory effects in the colon and rectum of germ-free mice than either KCO or bacteria alone. Similarly, p-p38-, CD3-, and CD79a-positive immune cells were more abundant in combined treatment group mice than in either single treatment group. Our study shows that KCO-degrading bacteria and the low MW products of KCO can promote proinflammatory effects in mice, and represent two key markers for evaluating CGN safety in foods or medicines. Carrageenan oligosaccharides Elsevier Intestinal inflammatory Elsevier Germ-free mouse Elsevier Oligosaccharide degrading bacteria Elsevier Carrageenans Elsevier Li, Miaomiao oth Gu, Weizhong oth Zeng, Benhua oth Liu, Wei oth Zhu, Liying oth Pi, Xionge oth Primerano, Donald A. oth Yu, Hongwei D. oth Wei, Hong oth Yu, Guangli oth Wang, Xin oth Enthalten in Elsevier Balazs, George C. ELSEVIER Outcomes and complications of triceps tendon repair following acute rupture in American military personnel 2016 JGG Amsterdam [u.a.] (DE-627)ELV024886548 volume:48 year:2021 number:9 day:20 month:09 pages:815-824 extent:10 https://doi.org/10.1016/j.jgg.2021.08.001 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_20 GBV_ILN_110 GBV_ILN_121 GBV_ILN_130 GBV_ILN_370 GBV_ILN_2011 GBV_ILN_2031 GBV_ILN_2046 58.10 Verfahrenstechnik: Allgemeines VZ AR 48 2021 9 20 0920 815-824 10 |
| allfieldsGer |
10.1016/j.jgg.2021.08.001 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001629.pica (DE-627)ELV055570380 (ELSEVIER)S1673-8527(21)00245-9 DE-627 ger DE-627 rakwb eng 610 VZ 660 VZ 660 VZ 58.10 bkl Yin, Yeshi verfasserin aut Carrageenan oligosaccharides and associated carrageenan-degrading bacteria induce intestinal inflammation in germ-free mice 2021transfer abstract 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Carrageenans (CGNs) are widely used in foods and pharmaceuticals although their safety remains controversial. To investigate the effects of CGNs and CGN-degrading bacteria in the human colon, we screened for CGN degradation by human fecal microbiota, and for inflammatory response to CGNs and/or CGN-degrading bacteria in germ free mice. Thin-layer chromatography indicated that high molecular weight (MW) CGNs (≥100 kDa) remained undegraded in the presence of human fecal microbiota, whereas low MW CGNs, i.e., κ-carrageenan oligosaccharides (KCO, ~4.5 kDa) were degraded when exposed to seven of eight human fecal samples, although sulfate groups were not removed during degradation. Bacteroides xylanisolvens and Escherichia coli isolates from fecal samples apparently degraded KCO synergistically, with B. xylanisolvens serving as the primary degrader. Combined treatment of KCO with KCO-degrading bacteria led to greater pro-inflammatory effects in the colon and rectum of germ-free mice than either KCO or bacteria alone. Similarly, p-p38-, CD3-, and CD79a-positive immune cells were more abundant in combined treatment group mice than in either single treatment group. Our study shows that KCO-degrading bacteria and the low MW products of KCO can promote proinflammatory effects in mice, and represent two key markers for evaluating CGN safety in foods or medicines. Carrageenans (CGNs) are widely used in foods and pharmaceuticals although their safety remains controversial. To investigate the effects of CGNs and CGN-degrading bacteria in the human colon, we screened for CGN degradation by human fecal microbiota, and for inflammatory response to CGNs and/or CGN-degrading bacteria in germ free mice. Thin-layer chromatography indicated that high molecular weight (MW) CGNs (≥100 kDa) remained undegraded in the presence of human fecal microbiota, whereas low MW CGNs, i.e., κ-carrageenan oligosaccharides (KCO, ~4.5 kDa) were degraded when exposed to seven of eight human fecal samples, although sulfate groups were not removed during degradation. Bacteroides xylanisolvens and Escherichia coli isolates from fecal samples apparently degraded KCO synergistically, with B. xylanisolvens serving as the primary degrader. Combined treatment of KCO with KCO-degrading bacteria led to greater pro-inflammatory effects in the colon and rectum of germ-free mice than either KCO or bacteria alone. Similarly, p-p38-, CD3-, and CD79a-positive immune cells were more abundant in combined treatment group mice than in either single treatment group. Our study shows that KCO-degrading bacteria and the low MW products of KCO can promote proinflammatory effects in mice, and represent two key markers for evaluating CGN safety in foods or medicines. Carrageenan oligosaccharides Elsevier Intestinal inflammatory Elsevier Germ-free mouse Elsevier Oligosaccharide degrading bacteria Elsevier Carrageenans Elsevier Li, Miaomiao oth Gu, Weizhong oth Zeng, Benhua oth Liu, Wei oth Zhu, Liying oth Pi, Xionge oth Primerano, Donald A. oth Yu, Hongwei D. oth Wei, Hong oth Yu, Guangli oth Wang, Xin oth Enthalten in Elsevier Balazs, George C. ELSEVIER Outcomes and complications of triceps tendon repair following acute rupture in American military personnel 2016 JGG Amsterdam [u.a.] (DE-627)ELV024886548 volume:48 year:2021 number:9 day:20 month:09 pages:815-824 extent:10 https://doi.org/10.1016/j.jgg.2021.08.001 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_20 GBV_ILN_110 GBV_ILN_121 GBV_ILN_130 GBV_ILN_370 GBV_ILN_2011 GBV_ILN_2031 GBV_ILN_2046 58.10 Verfahrenstechnik: Allgemeines VZ AR 48 2021 9 20 0920 815-824 10 |
| allfieldsSound |
10.1016/j.jgg.2021.08.001 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001629.pica (DE-627)ELV055570380 (ELSEVIER)S1673-8527(21)00245-9 DE-627 ger DE-627 rakwb eng 610 VZ 660 VZ 660 VZ 58.10 bkl Yin, Yeshi verfasserin aut Carrageenan oligosaccharides and associated carrageenan-degrading bacteria induce intestinal inflammation in germ-free mice 2021transfer abstract 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Carrageenans (CGNs) are widely used in foods and pharmaceuticals although their safety remains controversial. To investigate the effects of CGNs and CGN-degrading bacteria in the human colon, we screened for CGN degradation by human fecal microbiota, and for inflammatory response to CGNs and/or CGN-degrading bacteria in germ free mice. Thin-layer chromatography indicated that high molecular weight (MW) CGNs (≥100 kDa) remained undegraded in the presence of human fecal microbiota, whereas low MW CGNs, i.e., κ-carrageenan oligosaccharides (KCO, ~4.5 kDa) were degraded when exposed to seven of eight human fecal samples, although sulfate groups were not removed during degradation. Bacteroides xylanisolvens and Escherichia coli isolates from fecal samples apparently degraded KCO synergistically, with B. xylanisolvens serving as the primary degrader. Combined treatment of KCO with KCO-degrading bacteria led to greater pro-inflammatory effects in the colon and rectum of germ-free mice than either KCO or bacteria alone. Similarly, p-p38-, CD3-, and CD79a-positive immune cells were more abundant in combined treatment group mice than in either single treatment group. Our study shows that KCO-degrading bacteria and the low MW products of KCO can promote proinflammatory effects in mice, and represent two key markers for evaluating CGN safety in foods or medicines. Carrageenans (CGNs) are widely used in foods and pharmaceuticals although their safety remains controversial. To investigate the effects of CGNs and CGN-degrading bacteria in the human colon, we screened for CGN degradation by human fecal microbiota, and for inflammatory response to CGNs and/or CGN-degrading bacteria in germ free mice. Thin-layer chromatography indicated that high molecular weight (MW) CGNs (≥100 kDa) remained undegraded in the presence of human fecal microbiota, whereas low MW CGNs, i.e., κ-carrageenan oligosaccharides (KCO, ~4.5 kDa) were degraded when exposed to seven of eight human fecal samples, although sulfate groups were not removed during degradation. Bacteroides xylanisolvens and Escherichia coli isolates from fecal samples apparently degraded KCO synergistically, with B. xylanisolvens serving as the primary degrader. Combined treatment of KCO with KCO-degrading bacteria led to greater pro-inflammatory effects in the colon and rectum of germ-free mice than either KCO or bacteria alone. Similarly, p-p38-, CD3-, and CD79a-positive immune cells were more abundant in combined treatment group mice than in either single treatment group. Our study shows that KCO-degrading bacteria and the low MW products of KCO can promote proinflammatory effects in mice, and represent two key markers for evaluating CGN safety in foods or medicines. Carrageenan oligosaccharides Elsevier Intestinal inflammatory Elsevier Germ-free mouse Elsevier Oligosaccharide degrading bacteria Elsevier Carrageenans Elsevier Li, Miaomiao oth Gu, Weizhong oth Zeng, Benhua oth Liu, Wei oth Zhu, Liying oth Pi, Xionge oth Primerano, Donald A. oth Yu, Hongwei D. oth Wei, Hong oth Yu, Guangli oth Wang, Xin oth Enthalten in Elsevier Balazs, George C. ELSEVIER Outcomes and complications of triceps tendon repair following acute rupture in American military personnel 2016 JGG Amsterdam [u.a.] (DE-627)ELV024886548 volume:48 year:2021 number:9 day:20 month:09 pages:815-824 extent:10 https://doi.org/10.1016/j.jgg.2021.08.001 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_20 GBV_ILN_110 GBV_ILN_121 GBV_ILN_130 GBV_ILN_370 GBV_ILN_2011 GBV_ILN_2031 GBV_ILN_2046 58.10 Verfahrenstechnik: Allgemeines VZ AR 48 2021 9 20 0920 815-824 10 |
| language |
English |
| source |
Enthalten in Outcomes and complications of triceps tendon repair following acute rupture in American military personnel Amsterdam [u.a.] volume:48 year:2021 number:9 day:20 month:09 pages:815-824 extent:10 |
| sourceStr |
Enthalten in Outcomes and complications of triceps tendon repair following acute rupture in American military personnel Amsterdam [u.a.] volume:48 year:2021 number:9 day:20 month:09 pages:815-824 extent:10 |
| format_phy_str_mv |
Article |
| bklname |
Verfahrenstechnik: Allgemeines |
| institution |
findex.gbv.de |
| topic_facet |
Carrageenan oligosaccharides Intestinal inflammatory Germ-free mouse Oligosaccharide degrading bacteria Carrageenans |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Outcomes and complications of triceps tendon repair following acute rupture in American military personnel |
| authorswithroles_txt_mv |
Yin, Yeshi @@aut@@ Li, Miaomiao @@oth@@ Gu, Weizhong @@oth@@ Zeng, Benhua @@oth@@ Liu, Wei @@oth@@ Zhu, Liying @@oth@@ Pi, Xionge @@oth@@ Primerano, Donald A. @@oth@@ Yu, Hongwei D. @@oth@@ Wei, Hong @@oth@@ Yu, Guangli @@oth@@ Wang, Xin @@oth@@ |
| publishDateDaySort_date |
2021-01-20T00:00:00Z |
| hierarchy_top_id |
ELV024886548 |
| dewey-sort |
3610 |
| id |
ELV055570380 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV055570380</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626041840.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220105s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jgg.2021.08.001</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001629.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV055570380</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1673-8527(21)00245-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">660</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">660</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">58.10</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Yin, Yeshi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Carrageenan oligosaccharides and associated carrageenan-degrading bacteria induce intestinal inflammation in germ-free mice</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">10</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Carrageenans (CGNs) are widely used in foods and pharmaceuticals although their safety remains controversial. To investigate the effects of CGNs and CGN-degrading bacteria in the human colon, we screened for CGN degradation by human fecal microbiota, and for inflammatory response to CGNs and/or CGN-degrading bacteria in germ free mice. Thin-layer chromatography indicated that high molecular weight (MW) CGNs (≥100 kDa) remained undegraded in the presence of human fecal microbiota, whereas low MW CGNs, i.e., κ-carrageenan oligosaccharides (KCO, ~4.5 kDa) were degraded when exposed to seven of eight human fecal samples, although sulfate groups were not removed during degradation. Bacteroides xylanisolvens and Escherichia coli isolates from fecal samples apparently degraded KCO synergistically, with B. xylanisolvens serving as the primary degrader. Combined treatment of KCO with KCO-degrading bacteria led to greater pro-inflammatory effects in the colon and rectum of germ-free mice than either KCO or bacteria alone. Similarly, p-p38-, CD3-, and CD79a-positive immune cells were more abundant in combined treatment group mice than in either single treatment group. Our study shows that KCO-degrading bacteria and the low MW products of KCO can promote proinflammatory effects in mice, and represent two key markers for evaluating CGN safety in foods or medicines.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Carrageenans (CGNs) are widely used in foods and pharmaceuticals although their safety remains controversial. To investigate the effects of CGNs and CGN-degrading bacteria in the human colon, we screened for CGN degradation by human fecal microbiota, and for inflammatory response to CGNs and/or CGN-degrading bacteria in germ free mice. Thin-layer chromatography indicated that high molecular weight (MW) CGNs (≥100 kDa) remained undegraded in the presence of human fecal microbiota, whereas low MW CGNs, i.e., κ-carrageenan oligosaccharides (KCO, ~4.5 kDa) were degraded when exposed to seven of eight human fecal samples, although sulfate groups were not removed during degradation. Bacteroides xylanisolvens and Escherichia coli isolates from fecal samples apparently degraded KCO synergistically, with B. xylanisolvens serving as the primary degrader. Combined treatment of KCO with KCO-degrading bacteria led to greater pro-inflammatory effects in the colon and rectum of germ-free mice than either KCO or bacteria alone. Similarly, p-p38-, CD3-, and CD79a-positive immune cells were more abundant in combined treatment group mice than in either single treatment group. Our study shows that KCO-degrading bacteria and the low MW products of KCO can promote proinflammatory effects in mice, and represent two key markers for evaluating CGN safety in foods or medicines.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Carrageenan oligosaccharides</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Intestinal inflammatory</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Germ-free mouse</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Oligosaccharide degrading bacteria</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Carrageenans</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Li, Miaomiao</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gu, Weizhong</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zeng, Benhua</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Liu, Wei</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhu, Liying</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pi, Xionge</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Primerano, Donald A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yu, Hongwei D.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wei, Hong</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yu, Guangli</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wang, Xin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Balazs, George C. ELSEVIER</subfield><subfield code="t">Outcomes and complications of triceps tendon repair following acute rupture in American military personnel</subfield><subfield code="d">2016</subfield><subfield code="d">JGG</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV024886548</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:48</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:9</subfield><subfield code="g">day:20</subfield><subfield code="g">month:09</subfield><subfield code="g">pages:815-824</subfield><subfield code="g">extent:10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jgg.2021.08.001</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_121</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_130</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2046</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">58.10</subfield><subfield code="j">Verfahrenstechnik: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">48</subfield><subfield code="j">2021</subfield><subfield code="e">9</subfield><subfield code="b">20</subfield><subfield code="c">0920</subfield><subfield code="h">815-824</subfield><subfield code="g">10</subfield></datafield></record></collection>
|
| author |
Yin, Yeshi |
| spellingShingle |
Yin, Yeshi ddc 610 ddc 660 bkl 58.10 Elsevier Carrageenan oligosaccharides Elsevier Intestinal inflammatory Elsevier Germ-free mouse Elsevier Oligosaccharide degrading bacteria Elsevier Carrageenans Carrageenan oligosaccharides and associated carrageenan-degrading bacteria induce intestinal inflammation in germ-free mice |
| authorStr |
Yin, Yeshi |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV024886548 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 660 - Chemical engineering |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 VZ 660 VZ 58.10 bkl Carrageenan oligosaccharides and associated carrageenan-degrading bacteria induce intestinal inflammation in germ-free mice Carrageenan oligosaccharides Elsevier Intestinal inflammatory Elsevier Germ-free mouse Elsevier Oligosaccharide degrading bacteria Elsevier Carrageenans Elsevier |
| topic |
ddc 610 ddc 660 bkl 58.10 Elsevier Carrageenan oligosaccharides Elsevier Intestinal inflammatory Elsevier Germ-free mouse Elsevier Oligosaccharide degrading bacteria Elsevier Carrageenans |
| topic_unstemmed |
ddc 610 ddc 660 bkl 58.10 Elsevier Carrageenan oligosaccharides Elsevier Intestinal inflammatory Elsevier Germ-free mouse Elsevier Oligosaccharide degrading bacteria Elsevier Carrageenans |
| topic_browse |
ddc 610 ddc 660 bkl 58.10 Elsevier Carrageenan oligosaccharides Elsevier Intestinal inflammatory Elsevier Germ-free mouse Elsevier Oligosaccharide degrading bacteria Elsevier Carrageenans |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
m l ml w g wg b z bz w l wl l z lz x p xp d a p da dap h d y hd hdy h w hw g y gy x w xw |
| hierarchy_parent_title |
Outcomes and complications of triceps tendon repair following acute rupture in American military personnel |
| hierarchy_parent_id |
ELV024886548 |
| dewey-tens |
610 - Medicine & health 660 - Chemical engineering |
| hierarchy_top_title |
Outcomes and complications of triceps tendon repair following acute rupture in American military personnel |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV024886548 |
| title |
Carrageenan oligosaccharides and associated carrageenan-degrading bacteria induce intestinal inflammation in germ-free mice |
| ctrlnum |
(DE-627)ELV055570380 (ELSEVIER)S1673-8527(21)00245-9 |
| title_full |
Carrageenan oligosaccharides and associated carrageenan-degrading bacteria induce intestinal inflammation in germ-free mice |
| author_sort |
Yin, Yeshi |
| journal |
Outcomes and complications of triceps tendon repair following acute rupture in American military personnel |
| journalStr |
Outcomes and complications of triceps tendon repair following acute rupture in American military personnel |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2021 |
| contenttype_str_mv |
zzz |
| container_start_page |
815 |
| author_browse |
Yin, Yeshi |
| container_volume |
48 |
| physical |
10 |
| class |
610 VZ 660 VZ 58.10 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Yin, Yeshi |
| doi_str_mv |
10.1016/j.jgg.2021.08.001 |
| dewey-full |
610 660 |
| title_sort |
carrageenan oligosaccharides and associated carrageenan-degrading bacteria induce intestinal inflammation in germ-free mice |
| title_auth |
Carrageenan oligosaccharides and associated carrageenan-degrading bacteria induce intestinal inflammation in germ-free mice |
| abstract |
Carrageenans (CGNs) are widely used in foods and pharmaceuticals although their safety remains controversial. To investigate the effects of CGNs and CGN-degrading bacteria in the human colon, we screened for CGN degradation by human fecal microbiota, and for inflammatory response to CGNs and/or CGN-degrading bacteria in germ free mice. Thin-layer chromatography indicated that high molecular weight (MW) CGNs (≥100 kDa) remained undegraded in the presence of human fecal microbiota, whereas low MW CGNs, i.e., κ-carrageenan oligosaccharides (KCO, ~4.5 kDa) were degraded when exposed to seven of eight human fecal samples, although sulfate groups were not removed during degradation. Bacteroides xylanisolvens and Escherichia coli isolates from fecal samples apparently degraded KCO synergistically, with B. xylanisolvens serving as the primary degrader. Combined treatment of KCO with KCO-degrading bacteria led to greater pro-inflammatory effects in the colon and rectum of germ-free mice than either KCO or bacteria alone. Similarly, p-p38-, CD3-, and CD79a-positive immune cells were more abundant in combined treatment group mice than in either single treatment group. Our study shows that KCO-degrading bacteria and the low MW products of KCO can promote proinflammatory effects in mice, and represent two key markers for evaluating CGN safety in foods or medicines. |
| abstractGer |
Carrageenans (CGNs) are widely used in foods and pharmaceuticals although their safety remains controversial. To investigate the effects of CGNs and CGN-degrading bacteria in the human colon, we screened for CGN degradation by human fecal microbiota, and for inflammatory response to CGNs and/or CGN-degrading bacteria in germ free mice. Thin-layer chromatography indicated that high molecular weight (MW) CGNs (≥100 kDa) remained undegraded in the presence of human fecal microbiota, whereas low MW CGNs, i.e., κ-carrageenan oligosaccharides (KCO, ~4.5 kDa) were degraded when exposed to seven of eight human fecal samples, although sulfate groups were not removed during degradation. Bacteroides xylanisolvens and Escherichia coli isolates from fecal samples apparently degraded KCO synergistically, with B. xylanisolvens serving as the primary degrader. Combined treatment of KCO with KCO-degrading bacteria led to greater pro-inflammatory effects in the colon and rectum of germ-free mice than either KCO or bacteria alone. Similarly, p-p38-, CD3-, and CD79a-positive immune cells were more abundant in combined treatment group mice than in either single treatment group. Our study shows that KCO-degrading bacteria and the low MW products of KCO can promote proinflammatory effects in mice, and represent two key markers for evaluating CGN safety in foods or medicines. |
| abstract_unstemmed |
Carrageenans (CGNs) are widely used in foods and pharmaceuticals although their safety remains controversial. To investigate the effects of CGNs and CGN-degrading bacteria in the human colon, we screened for CGN degradation by human fecal microbiota, and for inflammatory response to CGNs and/or CGN-degrading bacteria in germ free mice. Thin-layer chromatography indicated that high molecular weight (MW) CGNs (≥100 kDa) remained undegraded in the presence of human fecal microbiota, whereas low MW CGNs, i.e., κ-carrageenan oligosaccharides (KCO, ~4.5 kDa) were degraded when exposed to seven of eight human fecal samples, although sulfate groups were not removed during degradation. Bacteroides xylanisolvens and Escherichia coli isolates from fecal samples apparently degraded KCO synergistically, with B. xylanisolvens serving as the primary degrader. Combined treatment of KCO with KCO-degrading bacteria led to greater pro-inflammatory effects in the colon and rectum of germ-free mice than either KCO or bacteria alone. Similarly, p-p38-, CD3-, and CD79a-positive immune cells were more abundant in combined treatment group mice than in either single treatment group. Our study shows that KCO-degrading bacteria and the low MW products of KCO can promote proinflammatory effects in mice, and represent two key markers for evaluating CGN safety in foods or medicines. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_20 GBV_ILN_110 GBV_ILN_121 GBV_ILN_130 GBV_ILN_370 GBV_ILN_2011 GBV_ILN_2031 GBV_ILN_2046 |
| container_issue |
9 |
| title_short |
Carrageenan oligosaccharides and associated carrageenan-degrading bacteria induce intestinal inflammation in germ-free mice |
| url |
https://doi.org/10.1016/j.jgg.2021.08.001 |
| remote_bool |
true |
| author2 |
Li, Miaomiao Gu, Weizhong Zeng, Benhua Liu, Wei Zhu, Liying Pi, Xionge Primerano, Donald A. Yu, Hongwei D. Wei, Hong Yu, Guangli Wang, Xin |
| author2Str |
Li, Miaomiao Gu, Weizhong Zeng, Benhua Liu, Wei Zhu, Liying Pi, Xionge Primerano, Donald A. Yu, Hongwei D. Wei, Hong Yu, Guangli Wang, Xin |
| ppnlink |
ELV024886548 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.jgg.2021.08.001 |
| up_date |
2024-07-06T17:55:04.315Z |
| _version_ |
1803853238702702592 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV055570380</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626041840.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220105s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jgg.2021.08.001</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001629.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV055570380</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1673-8527(21)00245-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">660</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">660</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">58.10</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Yin, Yeshi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Carrageenan oligosaccharides and associated carrageenan-degrading bacteria induce intestinal inflammation in germ-free mice</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">10</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Carrageenans (CGNs) are widely used in foods and pharmaceuticals although their safety remains controversial. To investigate the effects of CGNs and CGN-degrading bacteria in the human colon, we screened for CGN degradation by human fecal microbiota, and for inflammatory response to CGNs and/or CGN-degrading bacteria in germ free mice. Thin-layer chromatography indicated that high molecular weight (MW) CGNs (≥100 kDa) remained undegraded in the presence of human fecal microbiota, whereas low MW CGNs, i.e., κ-carrageenan oligosaccharides (KCO, ~4.5 kDa) were degraded when exposed to seven of eight human fecal samples, although sulfate groups were not removed during degradation. Bacteroides xylanisolvens and Escherichia coli isolates from fecal samples apparently degraded KCO synergistically, with B. xylanisolvens serving as the primary degrader. Combined treatment of KCO with KCO-degrading bacteria led to greater pro-inflammatory effects in the colon and rectum of germ-free mice than either KCO or bacteria alone. Similarly, p-p38-, CD3-, and CD79a-positive immune cells were more abundant in combined treatment group mice than in either single treatment group. Our study shows that KCO-degrading bacteria and the low MW products of KCO can promote proinflammatory effects in mice, and represent two key markers for evaluating CGN safety in foods or medicines.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Carrageenans (CGNs) are widely used in foods and pharmaceuticals although their safety remains controversial. To investigate the effects of CGNs and CGN-degrading bacteria in the human colon, we screened for CGN degradation by human fecal microbiota, and for inflammatory response to CGNs and/or CGN-degrading bacteria in germ free mice. Thin-layer chromatography indicated that high molecular weight (MW) CGNs (≥100 kDa) remained undegraded in the presence of human fecal microbiota, whereas low MW CGNs, i.e., κ-carrageenan oligosaccharides (KCO, ~4.5 kDa) were degraded when exposed to seven of eight human fecal samples, although sulfate groups were not removed during degradation. Bacteroides xylanisolvens and Escherichia coli isolates from fecal samples apparently degraded KCO synergistically, with B. xylanisolvens serving as the primary degrader. Combined treatment of KCO with KCO-degrading bacteria led to greater pro-inflammatory effects in the colon and rectum of germ-free mice than either KCO or bacteria alone. Similarly, p-p38-, CD3-, and CD79a-positive immune cells were more abundant in combined treatment group mice than in either single treatment group. Our study shows that KCO-degrading bacteria and the low MW products of KCO can promote proinflammatory effects in mice, and represent two key markers for evaluating CGN safety in foods or medicines.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Carrageenan oligosaccharides</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Intestinal inflammatory</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Germ-free mouse</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Oligosaccharide degrading bacteria</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Carrageenans</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Li, Miaomiao</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gu, Weizhong</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zeng, Benhua</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Liu, Wei</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhu, Liying</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pi, Xionge</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Primerano, Donald A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yu, Hongwei D.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wei, Hong</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yu, Guangli</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wang, Xin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Balazs, George C. ELSEVIER</subfield><subfield code="t">Outcomes and complications of triceps tendon repair following acute rupture in American military personnel</subfield><subfield code="d">2016</subfield><subfield code="d">JGG</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV024886548</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:48</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:9</subfield><subfield code="g">day:20</subfield><subfield code="g">month:09</subfield><subfield code="g">pages:815-824</subfield><subfield code="g">extent:10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jgg.2021.08.001</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_121</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_130</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2046</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">58.10</subfield><subfield code="j">Verfahrenstechnik: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">48</subfield><subfield code="j">2021</subfield><subfield code="e">9</subfield><subfield code="b">20</subfield><subfield code="c">0920</subfield><subfield code="h">815-824</subfield><subfield code="g">10</subfield></datafield></record></collection>
|
| score |
7.4007425 |